ClinicalTrials.gg
CompletedNCT03532854Updated Feb 15, 2019

Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

A Phase 1 interventional study of Valsartan and Ezetimibe/Rosuvastatin in Healthy Male Volunteers, sponsored by LG Chem. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by LG Chem · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and LGEV1802 in healthy male volunteers.

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male
  • Age between 19 and 50
  • Subjects with of 18\~27 kg/m2 with a weight of 55kg or more
  • Subjects with SBP of 90\~150 mmHg and DBP of 60\~150 mmHg
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Presence of medical history or a concurrent disease
  • Has a history of to IP ingredients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Sequence A

    Ezetimibe/Rosuvastatin -\> Valsartan -\> Valsartan and Ezetimibe/Rosuvastatin

    Drug: Valsartan · Drug: Ezetimibe/Rosuvastatin

  • Experimental
    Sequence B

    Valsartan -\> Valsartan and Ezetimibe/Rosuvastatin-\> Ezetimibe/Rosuvastatin

    Drug: Valsartan · Drug: Ezetimibe/Rosuvastatin

  • Experimental
    Sequence C

    Valsartan and Ezetimibe/Rosuvastatin -\> Ezetimibe/Rosuvastatin -\> Valsartan

    Drug: Valsartan · Drug: Ezetimibe/Rosuvastatin

  • Experimental
    Sequence D

    Ezetimibe/Rosuvastatin -\> Valsartan and Ezetimibe/Rosuvastatin-\> Valsartan

    Drug: Valsartan · Drug: Ezetimibe/Rosuvastatin

  • Experimental
    Sequence E

    Valsartan -\> Ezetimibe/Rosuvastatin -\> Valsartan and Ezetimibe/Rosuvastatin

    Drug: Valsartan · Drug: Ezetimibe/Rosuvastatin

  • Experimental
    Sequence F

    Valsartan and Ezetimibe/Rosuvastatin -\> Valsartan -\> Ezetimibe/Rosuvastatin

    Drug: Valsartan · Drug: Ezetimibe/Rosuvastatin

Interventions

  • Valsartan P.O

    Also known as: Diovan

  • DrugEzetimibe/Rosuvastatin

    Ezetimibe/Rosuvastatin P.O

    Also known as: Rosuzet

06

What researchers measure

Primary outcomes

  1. AUCT,ss

    Time frame: Day 1~Day 8

  2. Cmax,ss

    Time frame: Day 1~ Day 8

07

Study locations

1 site
  • LG chem
    Seoul, Gangseo-Gu 07795, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Aug 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2018
First posted
May 22, 2018
StartActual
May 28, 2018
Primary completionActual
Aug 25, 2018
CompletionActual
Jan 30, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03532854
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
May 22, 2018
Start date
May 28, 2018
Primary completion
Aug 25, 2018
Completion
Jan 30, 2019
Last update
Feb 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion